Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study.

Autor:	Azuma T; Azuma Rheumatology Clinic, Saitama, Japan., Misaki K; Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan., Kusaoi M; Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Suzuki Y; Izumi Himawari Clinic, Miyagi, Japan., Higa S; Division of Rheumatology, Daini Osaka Police Hospital, Osaka, Japan., Kumon Y; Department of Rheumatology, Chikamori Hospital, Kochi, Japan., Yoshitama T; Yoshitama Clinic for Rheumatic Diseases, Kagoshima, Japan., Naniwa T; Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University, Aichi, Japan., Yamada S; Department of Clinical Immunology, Osaka City University, Osaka, Japan., Okano T; Department of Orthopedic Surgery, Osaka City University, Osaka, Japan., Takeuchi K; Departments of Orthopedics and Rheumatology, Isesaki Fukushima Hospital, Gunma, Japan., Ikeda K; Department of Allergy and Clinical Immunology, Chiba University, Chiba, Japan., Higami K; Higami Clinic of Rheumatology and Diabetology, Nara, Japan., Inoo M; Utazu Hospital, Kagawa, Japan., Sawada T; Department of Rheumatology, Tokyo Medical University, Tokyo, Japan., Kang C; Kang Clinic Rheumatology Orthopedic, Kanagawa, Japan., Hayashi M; Hayashi Rheumatology Orthopaedic Clinic, Nagano, Japan., Nagaya Y; Center of Joint Surgery for Rheumatic Diseases and Osteoporosis, Nagoya City University East Medical Center, Aichi, Japan., Hagiwara T; Department of Rheumatology, Takarazuka City Hospital, Hyogo, Japan., Shono E; Shono Rheumatology Clinic, Fukuoka, Japan., Himeno S; Himeno Hospital, Fukuoka, Japan., Tanaka E; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan., Inoue E; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.; Showa University Research Administration Center, Showa University, Tokyo, Japan., Yoshizawa Y; Department of Immunology Medical, Bristol-Myers Squibb K.K., Tokyo, Japan., Kadode M; Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan., Yamanaka H; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.; Department of Rheumatology, Sanno Medical Center, Tokyo, Japan., Harigai M; Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Modern rheumatology [Mod Rheumatol] 2023 Mar 02; Vol. 33 (2), pp. 271-278.
DOI:	10.1093/mr/roac032
Abstrakt:	Objectives: We performed post-hoc analyses of the ORIGAMI study to investigate whether concomitant methotrexate (MTX) influences the clinical outcomes of abatacept in biologic-naïve patients with rheumatoid arthritis. Methods: Enrolled patients (n = 325) were divided into two groups according to whether abatacept was prescribed without (MTX-) or with (MTX+) concomitant MTX. We compared the changes in Simplified Disease Activity Index (SDAI), Disease Activity Score-28 with C-reactive protein (DAS28-CRP), and Japanese Health Assessment Questionnaire (J-HAQ) through to 52 weeks of treatment, the abatacept retention rate, and safety. Results: At Week 52, the mean SDAI (8.9 vs. 8.8), DAS28-CRP (2.6 vs. 2.6), and J-HAQ (0.92 vs. 0.91) scores were comparable in the MTX- (n = 129) and MTX+ (n = 150) groups. Multivariable logistic regression revealed no significant association between MTX use and SDAI (low disease activity) or J-HAQ (minimum clinically important difference). The abatacept retention rates, estimated using the Kaplan-Meier method, were 73.2% and 66.7% in the MTX- and MTX+ groups, respectively. Adverse events occurred in 47.5% (of 139) and 52.2% (of 159) of patients in the MTX- and MTX+ groups, respectively. Conclusion: The effectiveness and safety of abatacept appeared comparable with or without concomitant MTX in this real-world clinical setting. (© Japan College of Rheumatology 2022. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu